Table of Contents
Leukemia Research and Treatment
Volume 2013 (2013), Article ID 629283, 4 pages
http://dx.doi.org/10.1155/2013/629283
Clinical Study

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?

1Department of Pharmacy, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive Tampa, FL 33612, USA
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive Tampa, FL 33612, USA

Received 11 July 2013; Accepted 28 August 2013

Academic Editor: Massimo Breccia

Copyright © 2013 Jolly Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Atmar, “Review of the safety and feasibility of rapid infusion of rituximab,” Journal of Oncology Practice, vol. 6, no. 2, pp. 91–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. Rituxan, South San Francisco, CA. Genentech, 2010.
  3. A. Salar, D. Casao, M. Cervera et al., “Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-Yr experience in a single institution,” European Journal of Haematology, vol. 77, no. 4, pp. 338–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. H. J. van Oers, M. van Glabbeke, L. Giurgea et al., “Rituximab maintenance treatment of relapsed/resistant follicular non-hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study,” Journal of Clinical Oncology, vol. 28, no. 17, pp. 2853–2858, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. A. Salles, J. F. Seymour, P. Feugier et al., “Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunotherapy,” Journal of Clinical Oncology, vol. 28, no. 155, 2010. View at Google Scholar
  6. M. Provencio, S. Cerdeira, F. Bonilla, A. Sánchez, and P. España, “Rapid-infusion rituximab in lymphoma treatment,” Annals of Oncology, vol. 17, no. 6, pp. 1027–1028, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Siano, E. Lerch, L. Negretti et al., “A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function,” Clinical Cancer Research, vol. 14, no. 23, pp. 7935–7939, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. H. Sehn, J. Donaldson, A. Filewich et al., “Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting,” Blood, vol. 109, no. 10, pp. 4171–4173, 2007. View at Publisher · View at Google Scholar · View at Scopus